Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1576200 | 1.00 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Hydrochloric Acid SCHEMBL6531420 | 0.96 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL243698 | 0.96 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL5354209 | 0.96 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL243697 | 0.96 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL3693753 | 0.94 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Hydrochloric Acid SCHEMBL6357655 | 0.92 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL7053780 | 0.90 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL6355270 | 0.90 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Bromide SCHEMBL1539270 | 0.89 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | claimed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | claimed |
| EP-3504217-A1 | METHODS FOR CROSS COUPLING | Zeno Royalties & Milestones, LLC (US) | 2019-07-03 | — | — | EP | claimed |
| WO-2018039232-A1 | METHODS FOR CROSS COUPLING | KALYRA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | claimed |
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | disclosed |
| EP-3504217-A1 | METHODS FOR CROSS COUPLING | Zeno Royalties & Milestones, LLC (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039232-A1 | METHODS FOR CROSS COUPLING | KALYRA PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2013041106-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS 11CO FOR CARBONYLATION REACTIONS IN THE PREPARATION OF RADIOPHARMACEUTICALS FOR PET IMAGING | AARHUS UNIVERSITET (DK) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | F2, C5, C9 | GABRA1 1696/4885GABRG2 1747/4885GABRB3 2273/4885 |
| US-10793504-B2 | Methods for cross coupling | F2, C5, C9 | GABRA1 1696/4885GABRG2 1747/4885GABRB3 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.